

Date: 29-05-2023

To,
Cooperate Relation Department
The BSE LIMITED

1st Floor, Phiroze leejeebhoy Towers,
Dalal Street,
Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Year Ended on 31st March, 2023.

Please find enclosed herewith Newspaper clippings of Audited Financial Results for the quarter and year ended on 31st March, 2023 published in FREE PRESS JOURNAL and NAVSHAKTI on 28th May, 2023 in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on 27th May, 2023.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully,

For Colinz Laboratories Ltd.,

Dr. Mani L. S.

Director & Company Secretary

DIN: 00825886

* Nav-Shakti-(Marathi paper) pared-28/5/2023

८ नव अशक्ति। मुंबई, रविवार, २८ मे २०२३

COLINZ LABORATORIES LIM

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078. (CIN NO: L24200MH1986PLC041128)

AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31st MARCH, 2023

(Rs. In "Lacs")						
		QUARTER ENDED			YEAR ENDED	
S.	PARTICULARS	Audited Un-Audited			Audited	
o. No.		31-Mar-23		31-Mar-22	31-Mar-23	31-Mar-22
		176.34	172.26	165.27	732.70	714.50
2	Revenue from Operations Net Profit/(Loss) for the period(before Tax, Exceptional and/or	15.78	13.26	12.40	59.98	48.03
3	Extraordinary Items). Net Profit/(Loss) for the period before Tax (after Exceptional	15.78	13.26	12.40	59.98	48.03
4	and/or Extraordinary Items). Net Profit/(Loss) for the period after Tax (after Exceptional	12.79	10.26	7.01	45.74	33.93
5	(Loss) for the period(after tax) and Other Comprehensive Income	9.98	8.51	3.80	45.17	39.61
6	(Net of Tax). Equity Share Capital(Face Value of Rs. 10/- each).	25.19	25.19	354.50	25.19	354.50
7	- (F I Po 40/ pach)	0.51 0.51		0.15 0.15		

1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 27th May ,2023.

2) The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.

3) The above results of the Company have been audited by the Statutory Auditors and they have issued an unqualified audit opinion on the same.

Previous figures have been regrouped/rearranged

MUMBAI. 27th May, 2023.

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO : £24200MH1986PLC041128 Dr. MANI L. S.

(Director & Company Secretary) (DIN NO: 00825886)

* FREE PRESS JOURNAL *
pared -28/5/2023

www.freepressjournal.in MUMBAI | SUNDAY | MAY 28, 2023

COLINZ LABORATORIES

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078. (CIN NO: L24200MH1986PLC041128)

EXTRACTS OF AUDITED RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH, 2023

S. No.	PARTICULARS	QUARTER ENDED			YEAR ENDED	
		Audited	Un-Audited	Audited	Audited	
		31-Mar-23	31-Dec-22	31-Mar-22	31-Mar-23	31-Mar-22
4	Revenue from Operations	176.34	172.26	165.27	732.70	714.50
2	Net Profit/(Loss) for the period(before Tax, Exceptional and/or Extraordinary Items).	15.78	13.26	12.40	59.98	48.03
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary Items).	15.78	13.26	12.40	59.98	48.03
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary Items).	12.79	10.26	7.01	45.74	33.93
5	Total Comprehensive Income for the period(Comprising Profit/ (Loss) for the period(after tax) and Other Comprehensive Income (Net of Tax).	9.98	8.51	3.80	45.17	39.61
6	Equity Share Capital (Face Value of Rs. 10/- each).	25.19	25.19	354.50	25.19	354.50
NO. STATE	- 10-10-40(-ach)	Contract of the	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			1 1 1 1 1 1 1 1 1

1) Basic

2) Diluted

1) The above Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 27th May, 2023.

The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.

een audited by the Statutory Auditors and they have issued an unqualified audit 3) The above results of the Company have opinion on the same.

Previous figures have been regrouped

Earning Per Share (Face value of Rs. 10/- each)

(not annulised) (in Rs.)

For and on behalf of the Board COLINZ LABORATORIES LTD. CIN NO: L24200MH1986PLC041128

0.74

0.74

1.82

1.82

0.41

0.41

0.51

0.51

0.15

0.15

Dr. MANI L. S. (Director & Company Secretary) (DIN NO: 00825886)

MUMBAI. 27th May, 2023